Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yes those who complete the main trial n=462.

But in the OLE, everyone who completed the trial and wants to participate gets the drug without a doubt

No matter the reasons; Covid and others - the OLE n completers was about 20% of the main trial completer n or about 93.

That is a hefty OLE dropout rate making conclusions less reliable because the leftover sample is no longer free of e.g. selection bias.